Stabilizing Mood and Sleep With Blue Blocking Eyewear in Bipolar Disorder - Trial NCT06271304
Access comprehensive clinical trial information for NCT06271304 through Pure Global AI's free database. This phase not specified trial is sponsored by Mental Health Services in the Capital Region, Denmark and is currently Not yet recruiting. The study focuses on Bipolar Disorder. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mental Health Services in the Capital Region, Denmark
Timeline & Enrollment
N/A
Mar 01, 2024
Jun 01, 2026
Primary Outcome
Manic symptoms
Summary
The study investigates whether add-on treatment with eyewear that blocks the short
 wavelengths of visible light (500nm) reduces manic symptoms and improves sleep in patients
 receiving outpatient treatment as usual for bipolar disorder.
 
 When in a hypomanic or manic phase, participants will be randomized to receive add-on
 treatment with either blue blocking or low filtration eyewear from 18 PM to 8 AM daily for 7
 days.
 
 After this initial intervention phase, the eyewear is used daily for 3 months in either
 antimanic dose (14 hours) or maintenance dose (2 hours before bedtime).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06271304
Device Trial